- Trials with a EudraCT protocol (58)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
58 result(s) found for: Anti Dsdna Antibodies.
Displaying page 1 of 3.
EudraCT Number: 2019-003406-27 | Sponsor Protocol Number: SL0043 | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) DE (Ongoing) BG (Ongoing) HU (Completed) ES (Ongoing) AT (Prematurely Ended) GR (Ongoing) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) CZ (Completed) IT (Ongoing) DK (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005543-14 | Sponsor Protocol Number: CTU/2013/096 | Start Date*: 2016-07-19 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001645-41 | Sponsor Protocol Number: JAK115919 | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) EE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003246-93 | Sponsor Protocol Number: D3461C00008 | Start Date*: 2016-12-06 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ... | ||
Medical condition: Systemic Lupus Erythematosus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002984-14 | Sponsor Protocol Number: AC-064A201 | Start Date*: 2015-06-05 |
Sponsor Name:ACTELION Pharmaceuticals Ltd | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with sy... | ||
Medical condition: Systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003407-35 | Sponsor Protocol Number: SL0044 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) IT (Ongoing) DE (Trial now transitioned) PL (Ongoing) PT (Prematurely Ended) AT (Completed) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000962-14 | Sponsor Protocol Number: CCM-RNT-202101 | Start Date*: 2021-07-02 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005525-63 | Sponsor Protocol Number: C87044 | Start Date*: 2006-02-16 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Follow-up of study C87040 : Multicenter, single blind study to describe the efficacy and safety of re-treatment with CDP870 (certolizumab pegol) subcutaneous at 2 different dose regimens (400 mg i... | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005025-20 | Sponsor Protocol Number: CR0012 | Start Date*: 2018-03-21 |
Sponsor Name:UCB Biosciences, Inc. | ||
Full Title: An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the ... | ||
Medical condition: Crohn´s Disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-000488-17 | Sponsor Protocol Number: LUPIL-2 | Start Date*: 2016-08-08 | |||||||||||
Sponsor Name:ILTOO PHARMA | |||||||||||||
Full Title: A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ILT-101 in patients with active moderate to severe systemic lup... | |||||||||||||
Medical condition: Systematic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) PT (Completed) ES (Completed) BG (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001341-86 | Sponsor Protocol Number: IFN-K-002 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:Neovacs S.A. | |||||||||||||
Full Title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Syste... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) HR (Completed) ES (Completed) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004457-40 | Sponsor Protocol Number: SL0023 | Start Date*: 2016-09-19 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SU... | |||||||||||||
Medical condition: SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) RO (Completed) HU (Completed) BG (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004852-62 | Sponsor Protocol Number: FARM7KWBZ4 | Start Date*: 2009-02-09 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI | ||||||||||||||||||
Full Title: Safety and clinical efficacy of abetimus sodium (LJP-394) in prevention of renal flares in patients with systemic lupus erythematosus and a history of renal disease. | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000420-15 | Sponsor Protocol Number: B0151006 | Start Date*: 2012-06-21 | |||||||||||
Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | |||||||||||||
Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001203-79 | Sponsor Protocol Number: IM011021 | Start Date*: 2017-12-04 | |||||||||||
Sponsor Name:Bristol-Myers Squibb international Corporation | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) DE (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023396-25 | Sponsor Protocol Number: SM101-201-sle-10 | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:SuppreMol GmbH | |||||||||||||
Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000305-23 | Sponsor Protocol Number: BOS161721-02 | Start Date*: 2019-03-20 | |||||||||||
Sponsor Name:Boston Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care | |||||||||||||
Medical condition: Systemic lupus erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) HU (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003137-19 | Sponsor Protocol Number: M-2022-398 | Start Date*: 2023-05-30 | |||||||||||
Sponsor Name:Miltenyi Biomedicine GmbH | |||||||||||||
Full Title: An open-label phase I/IIa, multicenter, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE | |||||||||||||
Medical condition: Adult patients with refractory active systemic lupus erythematosus (SLE) with organ involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001269-40 | Sponsor Protocol Number: CT-1306 | Start Date*: 2008-10-29 |
Sponsor Name:Charité University Medicine | ||
Full Title: Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Th... | ||
Medical condition: Patients with systemic lupus erythematosus (SLE) will be under investigation who show high disease activity despite treatment with standard immunosuppressive therapies: high-dose corticosteroids an... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012059-47 | Sponsor Protocol Number: IFN-K-001 | Start Date*: 2010-01-28 | |||||||||||
Sponsor Name:Neovacs SA | |||||||||||||
Full Title: A phase I-II, randomized, double-blind, placebo-controlled, dose escalation study of Neovacs’ IFNα-Kinoid in adult subjects with Systemic Lupus Erythematosus. | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.